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The Src Inhibitor AZD0530 Blocks Invasion and May Act as
a Radiosensitizer in Lung Cancer Cells
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Tim P. Green, PhD,† Paul H. Gumerlock, PhD,* Primo N. Lara, MD,* David R. Gandara, MD,*
Hsing-Jien Kung, PhD,* and Oliver Gautschi, MD*‡
Background:With the emergence of Src inhibitors in clinical trials,
improved knowledge of the molecular responses of cancer cells to
these agents is warranted. This will facilitate the development of
tests to identify patients who may benefit from these agents, allow
drug activity to be monitored and rationalize the combination of
these agents with other treatment modalities.
Methods: This study evaluated the molecular and functional effects
of Src inhibitor AZD0530 in human lung cancer cells, by Western
blotting and reverse transcription-polymerase chain reaction, and by
assays for cell viability, migration, and invasion.
Results: Src was activated in four of five cell lines tested and the
level corresponded with the invasive potential and the histologic
subtype. Clinically relevant, submicromolar concentrations of
AZD0530 blocked Src and focal adhesion kinase, resulting in
significant inhibition of cell migration and Matrigel invasion. Reac-
tivation of STAT3 and up-regulation of JAK indicated a potential
mechanism of resistance. AZD0530 gave a potent and sustained
blockage of AKT and enhanced the sensitivity to irradiation.
Conclusions: The results indicated that AZD0530, aside from being
a potent inhibitor of tumor cell invasion which could translate to
inhibition of disease progression in the clinic, may also lower
resistance of lung cancer cells to pro-apoptotic signals.
Key Words: Lung cancer, Invasion, Metastasis, Src, Signal trans-
ducer and activator of transcription, Protein kinase B.
(J Thorac Oncol. 2009;4: 448–454)
Lung cancer is the leading cause of cancer-related deathamong men and women in the United States.1 Approxi-
mately, 80% of all lung cancer patients present with metas-
tases and are considered incurable. Systemic treatment for
these patients includes chemotherapy, angiogenesis inhibi-
tors, and epidermal growth factor receptor (EGFR) inhibitors.
Although these drugs can induce tumor responses, their
activity is only transient and additional treatment options are
needed. Due to the high invasive potential of lung cancer,
inhibition of invasion and metastasis is an appealing concept
in this tumor type. A large number of molecular factors
associated with lung cancer metastasis have been identified
and are currently being evaluated as drug targets.2,3
Src is part of a nine-member protein family of nonre-
ceptor tyrosine kinases (including Src, Yes, Yrk, Fyn, Fgr,
Lyn, Hck, Lck, and Blk). Src is closely associated with
growth factor and cytokine receptors and plays a key role in
the regulation of multiple cellular mechanisms, which are
important in both normal and cancer cells, including cell
migration, adhesion, invasion, survival, proliferation, angio-
genesis, and inflammation.4 Src regulates important intracel-
lular signaling pathways, including the focal adhesion kinase
(FAK), the phosphatidylinositol 3-kinase (PI3K), and the
signal transducer and activator of transcription 3 (STAT3)
pathways.5–7 Src is frequently overexpressed in lung cancer.
In non-small cell lung cancer (NSCLC), accounting for ap-
proximately 80% of all lung cancers, Src levels, determined
by immunoblotting and immunohistochemistry, were ele-
vated in 50 to 80% of samples tested, and Src expression
correlated with poor differentiation.8 The levels of activated
Src, determined by enolase-assays, were higher in lung can-
cers compared with adjacent normal tissue.9 Another study
revealed elevated Src kinase activity in NSCLC compared
with small cell lung cancer (SCLC).10 Activating mutations
of Src have been described in colon cancer, but as yet, neither
activating mutations nor gene amplifications have been de-
tected in lung cancer.11,12 In lung cancer cells, EGFR signal-
ing seems to be the dominant mechanism of Src activation.
This view is supported by studies demonstrating significant
induction of apoptosis by Src inhibition in EGFR-dependent
cell lines.13,14
A growing number of pharmacological Src inhibitors
are currently being tested in the clinic, but biomarker identi-
fication is still in early development.15 The dual Src/Abl
inhibitor dasatinib (BMS-354825) has shown preclinical an-
titumor activity in solid tumors and clinical activity in leu-
kemia.16 A six gene expression signature was shown to
predict the sensitivity of breast and lung cancer cells to
dasatinib in vitro,17 as did levels of activated Src in colon
cancer xenografts.18 The orally available Src inhibitor
AZD0530 is currently being tested in phase I-II trials. In
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breast cancer cells, AZD0530 reduced migration and, in
combination with tamoxifen, blocked proliferation.19 In or-
thotopic colon cancer and prostate cancer models, AZD0530
blocked metastasis.20,21 The present study evaluated the ef-
fects of AZD0530 in lung cancer cells and aimed to identify
molecular factors associated with drug response or resistance.
MATERIALS AND METHODS
Cell Lines
The NSCLC cell lines A549, Calu-1 and Calu-6 were
acquired from the American Type Culture Collection (Rock-
ville, MD). The SCLC cell lines H69 and H526 were pro-
vided by Dr. R. Bold (UC Davis Cancer Center). NSCLC
cells were cultured in DMEM (GIBCO, Carlsbad, CA) sup-
plemented with heat-inactivated sterile-filtered 10% fetal bo-
vine serum, 2 mM of L-glutamine, 100 U/ml of penicillin, and
100 g/ml of streptomycin. SCLC cells were cultured in
RPMI (GIBCO) supplemented with 10% fetal bovine serum,
1.5 mg/ml of sodium bicarbonate, 10 mM of HEPES, and 1
mM of sodium pyruvate. Cells were cultured at 37°C in a
humidified 5% CO2 atmosphere.
Reagents
AZD0530 (AstraZeneca, Macclesfield, UK), PP2 (EMD
Chemicals, Gibbstown, NJ), and LY294002 (Cell Signaling
Technology, Beverly, MA) were solubilized in dimethyl sulfox-
ide (DMSO) to 100 mM stock solutions.
Immunoprecipitation
Cells were harvested with trypsin-ethylenediaminetet-
raacetic acid and lysed with IP buffer containing 150 mM
NaCl, 25 mM Tris (pH 7.4), 1 mM ethylenediaminetetraace-
tic acid, 1 mM EGTA, 2 mM Na3VO4, 10 mM NaF, 1%
NP40, 10% glycerol, aprotinin (10 mg/ml), and leupeptin (10
mg/ml) for 30 minutes on ice. Lysates were centrifuged and
supernatants were collected. Equal amounts of protein were
incubated with total Src antibody (Upstate, Lake Placid, NY)
overnight at 4°C. Protein G was added and samples were
incubated at 4°C for 2 hours before pellets were rinsed twice
with IP buffer, resuspended in 15 L Laemmli buffer, and
boiled at 95°C for 5 minutes. The supernatant was separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis
and Western blotting was performed as described below.
Western Blotting
Protein extracts were prepared from cell pellets in
modified radioimmunoprecipitation assay buffer and proteins
were quantified using BCA assay (Pierce, Rockford, IL).
Equal amounts of protein were resolved by sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred
onto nitrocellulose membranes. Membranes were blocked
using 5% nonfat dry milk in Tris-buffered saline with Tri-
ton-X and incubated at 4°C overnight with the following
primary antibodies: Anti-Src and anti-FAK (Upstate, Lake
Placid, NY); antiphospho-Src family (Y419), anti-Abl, an-
tiphospho-Akt (S473), antiphospho-FAK (Y576/577), anti-
STAT3, antiphospho-STAT3 (Y705), anti-JAK1, anti-JAK2,
and anti-JAK3 (Cell Signaling Technology, Beverly, MA);
anti-Actin, and anti-Bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA); anti-Bcl-xL (Transduction Labs, Lexington, KY).
Membranes were incubated for 2 hours with appropriate
HRP-conjugated secondary antibodies (Promega, Madison,
WI) followed by visualization with enhanced chemilumines-
cent reagent and radiograph films (Amersham Biosciences,
Amersham, UK).
Migration and Invasion
Confluent monolayers of cells were scratched with a
sterile pipette tip. Cells were washed twice with phosphate-
buffered saline and incubated with AZD0530 at the concen-
trations indicated. Control cells were incubated with DMSO.
After 12 and 24 hours, migrating cells were photographed
and counted by microscopy. For invasion, transwell inserts
(BD Biosciences, San Jose, CA) were coated with 50 L of
Matrigel (BD Biosciences, Bedford, MA) and placed into
24-well plates. Cells (5  104) were placed into upper wells
in the presence of 1 M of AZD0530. Control cells were
incubated with DMSO. After 48 hours, cells in the upper
compartment were removed and cells on the lower side of the
filter were fixed with 3.7% formaldehyde, stained with 0.5%
methylene blue, photographed and counted by microscopy.
MTT Assay
Cells were plated (103 per well) in 96-well plates and
incubated with 1 M of AZD0530, 1 M of PP2, or 10 M
of LY294002. After 24 hours, plates were irradiated with
a single dose of 2, 5, or 10 Gy, using a 6 MV linear
accelerator (Varian, Palo Alto, CA). After another 72
hours, plates were analyzed using MTT. Cells were incubated
with 5 mg/ml MTT [3-4,5-dimethylthiazol-2-yl-2,5-diphe-
nyltetrazolium bromide] (Sigma-Aldrich, St. Louis, MO) for
3.5 hours at 37°C. The supernatant was removed, cells were
lysed in 100% DMSO for 15 minutes, and absorbance at 570
nm was measured on a Benchmark plus photometer (Bio-
Rad, Camarillo, CA). Control cells were incubated with
DMSO. All samples were performed in triplicate.
Quantitative Real Time Reverse Transcription-
Polymerase Chain Reaction
Total RNA was extracted using the Trizol protocol (In-
vitrogen, Carlsbad, CA) and 1 g of RNA was reversely
transcribed using the M-MuLV reverse transcriptase (Fermen-
tas, Hanover, MD). Equal amounts of cDNA were subjected to
quantitative real time polymerase chain reaction (PCR) using the
iQ Sybr Green Supermix and the iCycler detection system
(Biorad, Hercules, CA). Primers: JAK1-F 5-GGAAATCTGC-
TACAATGGCGAG-3; JAK1-R 5-CCCCTTACAAATCT-
GAACGGC-3, 18S-F 5-CGCCGCTAGAGGTGAAATTCT-
3, 18S-R 5-CGAACCTCCGACTTTCGTTCT-3. Standard
dilutions, melting curve analysis, and agarose gel electrophoresis
of PCR products were performed to confirm accuracy of the
method. Results were analyzed using Q-GENE software.22
JAK1 expression values were normalized for 18S rRNA and
compared with DMSO control.
Statistical Analysis
Each experiment was performed at least twice; values
represent the mean plus standard error of triplicate or qua-
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druplicate wells. Two-sided t-tests were used and p-values
0.05 were considered significant.
RESULTS
Target Validation
In a panel of five human lung cancer cell lines, basal
expression levels of activated and total Src were deter-
mined by Src-immunoprecipitation and Western blotting
for pY419-Src (Figure 1A). Overall, the levels of pSrc
corresponded to the levels of Src. The NSCLC cell lines
A549 and Calu-1 expressed the highest levels of pSrc and
Src, Calu-6 (NSCLC), and H69 (SCLC) cells expressed
moderate levels, and the SCLC cell line H526 expressed
undetectable levels of pSrc.
Next, A549 cells were incubated with AZD0530 at
concentrations ranging from 1 to 10,000 nM (time ranging
from 1 to 24 hours), followed by Src-immunoprecipitation
and Western blotting for pY419-Src (Figures 1B, C).
AZD0530 decreased pSrc levels in a time and dose dependent
way and had a potent effect at low nanomolar concentrations.
Total Src levels were not affected. Because AZD0530 has
moderate activity against Abl (IC50 30 nM) in addition to its
activity against Src, total levels of Abl were determined in the
five lung cancer cell lines (data not shown). Only H69 cells
expressed significant levels of Abl, which confirmed that Abl
was not highly expressed in most lung cancer cells.
Migration, Invasion, and FAK Signaling
A549 cells were grown to confluent monolayers, which
were scratched with a pipette tip and incubated with AZD0530
at concentrations ranging from 100 to 1000 nM (Figure 2A).
DMSO-treated control cells continuously migrated into the
scratch and nearly closed the scratch within 24 hours. Cell
migration was significantly inhibited by AZD0530 in a dose-
dependent way (Figure 2B). At the highest dose tested (1
M), AZD0530 reduced A549 cell migration by more than
60%. Cell invasion was tested using a modified Matrigel
assay with A549 (high Src levels) and Calu-6 (low Src levels)
cells (Figures 3A, B). Cells were incubated with DMSO or 1
M of AZD0530 for 48 hours. The invasive potential of
A549 cells was almost 10-fold higher compared with Calu-6
FIGURE 1. Target validation. A, Basal expression levels of
pY419-Src and total Src were determined by immunopre-
cipitation with anti-Src antibody followed by Western blot-
ting for pY419-Src and total Src. B, A549 cells were incu-
bated with AZD0530 for 24 hours at the doses indicated,
followed by immunoprecipitation and Western blotting as in
A. C, A549 cells incubated with 1 M of AZD0530 at the
times indicated, followed by immunoprecipitation and West-
ern blotting.
FIGURE 2. Effect on cell migration. A, Confluent monolay-
ers of A549 cells were scratched and incubated with di-
methyl sulfoxide (DMSO) or AZD0530 at 500 nM. Migrating
cells were photographed at 12 and 24 hours. B, Cells mi-
grating into the scratch were counted and represented as a
percentage of the DMSO control at 12 hours of incubation
with indicated doses of AZD0530. Results are expressed as
the mean  SEM of 3 independent experiments. Asterisks
represent two-sided t-tests with p-values 0.05.
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cells, reflecting the basal level of Src in these cells. AZD0530
significantly reduced Matrigel invasion in A549 and Calu-6
cells by 51 and 82%, respectively.
To study the effect of AZD0530 on FAK, A549 cells
were incubated with AZD0530 at concentrations in the range
of 100 to 1000 nM, followed by FAK-immunoprecipitation
and Western blotting for pY576-FAK (Figure 3C). AZD0530
at concentrations of 100 nM and 250 nM decreased the level
of pFAK, whereas total FAK levels remained unchanged.
AZD0530 concentrations above 500 nM decreased both
pFAK and total FAK levels.
Reactivation of the JAK-STAT3 Pathway
Basal expression levels of pY705-STAT3 and total
STAT3 in lung cancer cells were determined by Western
blotting (Figure 4A). All cell lines tested expressed STAT3.
pSTAT3 levels were highest in A549 and low in Calu-1,
consistent with a previous report.23 A549 cells were then
incubated with 500 nM of AZD0530 (Figure 4B). Western
blotting showed a short decrease of the pSTAT3 levels at 1
hour, and a rise at later time points. At the 24 hour time point,
incubation with AZD0530 led to a dose-dependent increase
of the pSTAT3 level (Figure 4C). Total STAT3 levels were
not affected.
Because JAK can activate STAT3, the basal expression
of JAK1-3 in lung cancer cells was determined (Figure 5A).
All cell lines expressed JAK1 and JAK2, but JAK3 was only
observed in Calu-6. A549 cells were incubated with
AZD0530 and JAK1-3 protein levels were determined by
Western blotting (Figure 5B). JAK1 mRNA levels were
measured by qRT-PCR. AZD0530 increased JAK1 mRNA
and JAK1-3 protein levels in a dose and time dependent way
(Figures 5B, C).
Inhibition of AKT and Enhancement of
Radiosensitivity
Basal expression of pS473-AKT, homo sapiens v-akt
murine thymoma viral oncogene homolog (AKT), Bcl-xL,
and Bcl-2 in lung cancer cells was determined by Western
blotting (Figure 6A). All cell lines tested expressed AKT.
pAKT levels corresponded with AKT, and Bcl-xL levels
(Figure 6A) corresponded with Src levels (Figure 1A). Bcl-2
FIGURE 3. Effect on Matrigel invasion. A, A549 cells were
plated in the upper chamber of a transwell coated with Matri-
gel with dimethyl sulfoxide (DMSO) or AZD0530 at 1 M. Af-
ter 48 hours, cells invading through the Matrigel were photo-
graphed. B, A549 and Calu-6 cells invading through the
Matrigel were fixed, stained with 0.5% methylene blue and
counted. Results presented as a percentage of the A549 DMSO
control (SEM of quadruplicate wells). C, A549 cells were incu-
bated with AZD0530 at indicated doses for 24 hours, followed
by focal adhesion kinase (FAK)-immunoprecipitation and West-
ern blotting for pY576-FAK and total FAK.
FIGURE 4. Reactivation of signal transducer and activator
of transcription 3 (STAT3). A, Basal expression levels of
pY705-STAT3 and total STAT3 were determined by Western
blotting in A549, Calu-1, Calu-6, H69, and H526 cell lines.
B, A549 cells were incubated with 500 nM of AZD0530 for
the times indicated, followed by Western blotting for pY705-
STAT and STAT3. C, A549 cells were incubated with indi-
cated doses of AZD0530 for 24 hours, followed by Western
blotting for pY705-STAT3 and STAT3.
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levels were higher in SCLC compared with NSCLC cells.
Next, A549 cells were incubated with AZD0530 or PP2
(another selective Src inhibitor24), at concentrations ranging
from 100 to 1000 nM (Figure 6B, C). AZD0530 and PP2
decreased pAKT and Bcl-xL levels in a dose dependent way,
whereas the levels of total AKT remained unchanged.
LY294002 is a selective inhibitor of PI3K-AKT and
has been shown to sensitize cancer cells to pro-apoptotic
signals.25,26 To examine whether AZD0530 and PP2 have a
similar effect, we performed irradiation experiments with
A549 and Calu-6 cells. Cells were incubated with DMSO
control, 1 and 10 M of AZD0530, 1 M of PP2 or 10 M
of LY294002 for 24 hours, followed by no irradiation, or
irradiation with a single dose of 2, 5, or 10 Gy (Figure 7A, B).
Irradiation alone had a dose dependent effect on cell viability
in the MTT assay, which was enhanced by AZD0530 and
LY294002, but not by PP2. To find an explanation for the
failure of PP2, A549 cells were incubated with AZD0530 or
PP2 over different periods of time (ranging from 1 to 48
hours), followed by Western blotting for pS473-AKT (Figure
7C). AZD0530 induced rapid and persistent suppression of
pAKT, whereas the effect of PP2 on pAKT was delayed and
transient.
DISCUSSION
The Src inhibitor AZD0530 is currently in phase I-II
trials in patients with cancer.15 The availability of molecular
markers to select patients and monitor drug effects may
greatly enhance the development of this agent, as well as
other Src inhibitors, in the clinic.
A previous report demonstrated that AZD0530 potently
reduced migration and invasion in human breast cancer cell
lines.19 The present study confirmed this effect in human lung
cancer cell lines. AZD0530 abrogated the levels of activated
Src, reduced the levels of activated FAK and significantly
blocked cell migration and Matrigel invasion (Figures 1–3).
Functional effects were achieved by a single administration
of AZD0530 in a range between 100 and 1000 nM. Whether
such concentrations can be reached in patients, remains to be
shown by clinical trials. It is also possible that off-target
activity of the compound may have contributed to these
effects to some degree. We observed a concordance between
the baseline level of activated Src, the histologic subtype and
the differential invasive potential of the cell lines. However,
AZD0530 blocked invasion irrespective of the level of acti-
vated Src in the cells, suggesting that other molecular mark-
FIGURE 5. Up-regulation of JAK. A, Basal expression levels
of JAK1, JAK2, and JAK3 were determined by Western blot-
ting. B, Incubation of A549 cells with 500 nM of AZD0530
for the times indicated, followed by Western blotting for
JAK1-3. C, Incubation of A549 cells with 500 nM of
AZD0530 cells for 24 hours, followed by JAK1 and 18S qRT-
PCR. JAK1 expression was normalized for 18S expression. D,
Incubation of A549 cells with AZD0530 for 24 hours fol-
lowed by JAK1 and 18S qRT-PCR.
FIGURE 6. Inhibition of AKT and Bcl-xL. A, Basal expression
of pS473-AKT, AKT, Bcl-xL, and Bcl-2 by Western blotting in
a panel of lung cancer cell lines. B, A549 cells were incu-
bated with increasing concentrations of PP2 for 24 hours,
followed by Western blotting for pS473-AKT, AKT, Bcl-xL
and Actin. C, A549 cells were incubated with AZD0530 for
24 hours at the doses indicated, followed by Western blot-
ting for pS473-AKT, AKT, Bcl-xL, and Actin.
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ers might be more informative, including FAK, paxillin, ERK
and other members of the integrin signaling pathway. In this
context, we recently demonstrated that AZD0530 targets the
bone morphogenetic protein signaling pathway and found
that the inhibitor of differentiation 1 (Id1) protein is a poten-
tial biomarker for Src inhibitor treatment.27 In the present
study, we studied the effect of AZD0530 on two other
important pathways regulated by Src.
In lung cancer cells, Src regulates the JAK-STAT3
pathway, which in turn promotes cell proliferation and sur-
vival.23,28 Consequently, the Src inhibitor SU6656 decreased
the levels of activated STAT3 and induced apoptosis in a
significant proportion of lung cancer cells in a previous
study.29 However, the Src inhibitor dasatinib induced reacti-
vation of STAT3 in lung cancer cells, similar to the effect of
doxorubicin in breast cancer cells.16,30 The present study
revealed that AZD0530 transiently lowered the levels of
activated STAT3, after a rapid dose and time dependent
reactivation of STAT3 (Figure 4). This was consistent with
the observation that clinically relevant concentrations of
AZD0530 had a negligible effect on cell viability and did not
significantly alter the expression of the STAT3-target genes
VEGF and IL-8 (data not shown). Also, the present study for
the first time to our knowledge, indicated that in lung cancer
cells, inhibition of Src induced up-regulation of JAK, sug-
gesting that JAK is involved in the compensatory reactivation
of STAT3 (Figure 5). Further studies are planned to confirm
these data.
Src also interacts with the PI3K-AKT pathway, which
regulates cell survival in a way that is partially overlapping
with the JAK-STAT pathway.25 Previous studies revealed
that cytotoxic drugs activate AKT and that inhibition of AKT
enhances the sensitivity to pro-apoptotic signals in cancer
cells.31,32 Consistent with these data, the present study dem-
onstrated that AZD0530 potently and sustainably blocked
AKT and enhanced the sensitivity of lung cancer cells to
irradiation (Figure 7). The effect of AZD0530 was compara-
ble with the effect of the PI3K-AKT inhibitor LY294002.
PP2 failed in combination with irradiation, likely because
PP2 is 5 to 10 times less potent than AZD0530. This may
explain the diverging results in previous studies including
PP2 in combination with irradiation and cytotoxic drugs in
breast and colon cancer cells, respectively.33,34
In conclusion, our results demonstrate that AZD0530
is a potent inhibitor of lung cancer cell migration and
invasion. Although this may be sufficient to provide clin-
ical benefit through inhibition of disease progression and
tumor spread, the profound inhibition of AKT and prelim-
inary data from the combination experiments suggest that
AZD0530 warrants further study in combination with
irradiation and chemotherapy.
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